158 related articles for article (PubMed ID: 31792264)
1. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
Munawar U; Roth M; Barrio S; Wajant H; Siegmund D; Bargou RC; Kortüm KM; Stühmer T
Sci Rep; 2019 Dec; 9(1):18062. PubMed ID: 31792264
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other.
Surget S; Lemieux-Blanchard E; Maïga S; Descamps G; Le Gouill S; Moreau P; Amiot M; Pellat-Deceunynck C
Leuk Lymphoma; 2014 Sep; 55(9):2165-73. PubMed ID: 24308434
[TBL] [Abstract][Full Text] [Related]
3. RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
Surget S; Descamps G; Brosseau C; Normant V; Maïga S; Gomez-Bougie P; Gouy-Colin N; Godon C; Béné MC; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
BMC Cancer; 2014 Jun; 14():437. PubMed ID: 24927749
[TBL] [Abstract][Full Text] [Related]
4. Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.
Gillardin PS; Descamps G; Maiga S; Tessoulin B; Djamai H; Lucani B; Chiron D; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C; Moreau-Aubry A
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295500
[TBL] [Abstract][Full Text] [Related]
5. A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R; Descamps G; Bellanger C; Dousset C; Maïga S; Alberge JB; Derrien J; Cruard J; Minvielle S; Lilli NL; Godon C; Le Bris Y; Tessoulin B; Amiot M; Gomez-Bougie P; Touzeau C; Moreau P; Chiron D; Moreau-Aubry A; Pellat-Deceunynck C
Blood; 2024 Mar; 143(13):1242-1258. PubMed ID: 38096363
[TBL] [Abstract][Full Text] [Related]
6. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
8. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
Surget S; Chiron D; Gomez-Bougie P; Descamps G; Ménoret E; Bataille R; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
Cancer Res; 2012 Sep; 72(17):4562-73. PubMed ID: 22738917
[TBL] [Abstract][Full Text] [Related]
9.
Watanabe S; Tsuchiya K; Nishimura R; Shirasaki T; Katsukura N; Hibiya S; Okamoto R; Nakamura T; Watanabe M
Mol Cancer Res; 2019 Jul; 17(7):1459-1467. PubMed ID: 30988165
[TBL] [Abstract][Full Text] [Related]
10. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
Xiang Y; Remily-Wood ER; Oliveira V; Yarde D; He L; Cheng JQ; Mathews L; Boucher K; Cubitt C; Perez L; Gauthier TJ; Eschrich SA; Shain KH; Dalton WS; Hazlehurst L; Koomen JM
Mol Cell Proteomics; 2011 Nov; 10(11):M110.005520. PubMed ID: 21846842
[TBL] [Abstract][Full Text] [Related]
11. Prognosis, Biology, and Targeting of
Flynt E; Bisht K; Sridharan V; Ortiz M; Towfic F; Thakurta A
Cells; 2020 Jan; 9(2):. PubMed ID: 31991614
[TBL] [Abstract][Full Text] [Related]
12. Proteometabolomics of Melphalan Resistance in Multiple Myeloma.
Koomen DC; Guingab-Cagmat JD; Oliveira PS; Fang B; Liu M; Welsh EA; Meads MB; Nguyen T; Meke L; Eschrich SA; Shain KH; Garrett TJ; Koomen JM
Methods Mol Biol; 2019; 1996():273-296. PubMed ID: 31127562
[TBL] [Abstract][Full Text] [Related]
13. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
Zub KA; Sousa MM; Sarno A; Sharma A; Demirovic A; Rao S; Young C; Aas PA; Ericsson I; Sundan A; Jensen ON; Slupphaug G
PLoS One; 2015; 10(3):e0119857. PubMed ID: 25769101
[TBL] [Abstract][Full Text] [Related]
14. Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support.
Gebauer N; Biersack H; Czerwinska AC; Schemme J; Hardel TT; Bernard V; Rades D; Lehnert H; Luley KB; Thorns C
Leuk Lymphoma; 2016; 57(6):1482-6. PubMed ID: 26414189
[No Abstract] [Full Text] [Related]
15. Elevation of the TP53 isoform Δ133p53β in glioblastomas: an alternative to mutant p53 in promoting tumor development.
Kazantseva M; Eiholzer RA; Mehta S; Taha A; Bowie S; Roth I; Zhou J; Joruiz SM; Royds JA; Hung NA; Slatter TL; Braithwaite AW
J Pathol; 2018 Sep; 246(1):77-88. PubMed ID: 29888503
[TBL] [Abstract][Full Text] [Related]
16.
Drozdkova DH; Gursky J; Minarik J; Überall I; Kolar Z; Trtkova KS
Anticancer Res; 2020 Sep; 40(9):4979-4987. PubMed ID: 32878786
[TBL] [Abstract][Full Text] [Related]
17. p53 haploinsufficiency and functional abnormalities in multiple myeloma.
Teoh PJ; Chung TH; Sebastian S; Choo SN; Yan J; Ng SB; Fonseca R; Chng WJ
Leukemia; 2014 Oct; 28(10):2066-74. PubMed ID: 24625551
[TBL] [Abstract][Full Text] [Related]
18. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.
Gkotzamanidou M; Sfikakis PP; Kyrtopoulos SA; Bamia C; Dimopoulos MA; Souliotis VL
Br J Cancer; 2014 Sep; 111(7):1293-304. PubMed ID: 25051404
[TBL] [Abstract][Full Text] [Related]
19. Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.
Rojas EA; Corchete LA; San-Segundo L; Martínez-Blanch JF; Codoñer FM; Paíno T; Puig N; García-Sanz R; Mateos MV; Ocio EM; Misiewicz-Krzeminska I; Gutiérrez NC
Clin Cancer Res; 2017 Nov; 23(21):6602-6615. PubMed ID: 28790111
[No Abstract] [Full Text] [Related]
20. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
